Connect with us


The Endocannabinoid System and Motor Control



The body is extraordinarily complex on a number of different levels. That complexity doesn’t stop with simply the complexity of structure. In fact some of the most dramatic complexity arises from how structure is utilized by the functioning of systemic processes.

One such systemic process that has baffled scientists for hundreds of years is motor control. This field of research has now extended to integrate research into the important role played by the endocannabinoid system.

Understanding Motor Control

Motor control refers to the cortical component in the brain-body relationship, whereby neurons activate in a sequence that controls the movement by voluntary process of the outer extremities of the body as well as the body’s chassis.

In effect, it is the control system that provides for voluntary coordination and movement of the skeletomuscular system.

But this isn’t just about the process of activating a movement. It also includes the thoughts behind the decision to make that movement and the perceptual input that gives rise to those thoughts.

In many cases, in fact, the movement is only partially voluntary, with instinctive responses contributing to the control process based on effectively automatic responses to incoming perceptual data.

In other words, if you’re driving down the road and someone swerves in front of you, you will find that your foot is on the brake pedal far before you ever realize what’s happening on a conscious level.

For all of this to come together in a productive manner, many aspects of the brain need to be working together in a synchronized manner. This includes major roles for different areas of the brain including the frontal lobe, the motor cortex, the cerebellum, and the basal ganglia.

Hence, the process of motor control incorporates our sensory perception, our decision-making, our memories, and our instinctive responses, and coordinates them all with the motor system of the brain, which more directly controls the nerves responsible for causing muscles to fire, thus driving movements in the body and limbs.

The Endocannabinoid System and Motor Control

One of the most important areas of the brain that implicates the significance of the endocannabinoid system in motor control is the basal ganglia.

The basal ganglia represents a grouping of structural components that are intimately linked with the thalamus, a structure located in the base of the brain. Essentially, we’re talking about a giant bundle of nerves where the body meets the brain that are integral to the coordination of movements in the body.

At this point, research has indicated that the endocannabinoid system plays a role in the process of motor control due to a high density of endocannabinoid receptors that are located in both the basal ganglia and the cerebellum.

This has led to the assumption that there must be a purpose to this high density of receptors. One theory at this point is that they provide protection and alleviation for motor symptoms and neurons that act to battle against a number of neurological problems.

This is evidenced by the important role played by cannabinoids in Parkinson’s, Alzheimer’s, and multiple sclerosis.

The big point to make here is this: an ineffective endocannabinoid system is thought to worsen problems of motor control. Therefore, by deduction, the use of cannabinoids such as CBD to improved deficiencies of the endocannabinoid system should be able to aid in benefiting individuals with their motor control.

While additional research is necessary, it would appear as though sufficient evidence is in place to suggest the benefits of investment in such research, and the potential for that research to yield insights into how CBD may play an important role in various disorders of the motor control system.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


WeedMD Inc (OTCMKTS:WDDMF) Signs A Pact With Fire & Flower To Manufacture CBD Cannabis Products: Will Announce Q2 2020 Revenues On September 24, 2020



WeedMD Inc (OTCMKTS:WDDMF) will submit the financial statements for Q2 2020 on September 24, 2020, within the 45 days window offered by the regulator. The auditors of WeedMD requested additional time to prepare and submit the results because of the ongoing coronavirus pandemic.

Signs a commercial arrangement with Fire & Flower

WeedMD entered a commercial pact with Fire & Flower for the manufacture of CBD cannabis products. As per the terms of the pact, WeedMD will produce, package, and transport Revity CBD products of Fire & Flower to the Saskatchewan provinces. The new products will hit the shelves of the retailer on August 14, 2020.

WeedMD will produce Revity CBD products at its most sophisticated extraction center – CX Industries, using its biomass. CEO of WeedMD, Angelo Tsebelis, said the company is excited to bag the contract order from Fire & Flower to produce Revity CBD products. It is the first commercial arrangement in Canada, and the company looks forward to working on this prestigious contract with Fire & Flower in its endeavor to introduce new products and enter strategic markets.

Angelo said the company intends to maintain a healthy longterm relationship with Fire & Flower by producing high-quality products using trichome rich biomass at its CX extraction hub. CEO of Fire & Flower, Trevor Fencott, said the company is excited to introduce its wellness-focused products to the underserved CBD markets.

Angelo further said WeedMD has an excellent track record in the production of high-quality products and leading innovation. After the initial launch in Saskatchewan, the Revity brand will be expanded nationwide.

Exclusive license accord to manufacture wellness products

WeedMD inked an exclusive license accord to manufacture Mary’s Medicinals wellness products. Under the terms of the deal with MM Technology Holdings, LLC, which holds Mary’s Medicinals product line and Mary’s brand, WeedMD will work as an exclusive partner for the production of Mary’s Medicinals products using its biomass at CX extraction center.

WeedMD will engage in the sale and distribution of Mary’s Medicinals’ products in Canada for medical use and adult use. CEO of Mary’s Brands, Jacques Panis, said the company is excited to partner with WeedMD to expand its Medicinals brands into Canada.

WeedMD posted revenues of $12 million in Q1 2020. It is driven by customer acquisition initiatives, Color Cannabis Brand recognition, and significant sales of biomass cultivated outdoors.

Continue Reading


Planet 13 Holdings Inc (OTCMKTS:PLNHF) Reports A Drop Of 34.9% In Q2 2020 Revenues



Planet 13 Holdings Inc (OTCMKTS:PLNHF) posted a decline of 34.9% YoY to $10.8 million in Q2 2020. It also reported a drop of 51.54% in gross profits to $4.7 million in Q2 2020. The company reduced the operational expenses by 18.5% to $5.8 million.

Preserves capital and adds new customers

Co-CEO of Planet 13, Larry Scheffler, said all the Nevada businesses faced challenges in Q2 2020. Despite the challenges, the Planet 13 put in significant efforts to preserve the capital and add new clients in Q2 2020.  After the states are reopened, Planet 13 gained momentum and reported better sales in July and August 2020.

Brands sales at superstores

Co-CEO of Planet 13, Bob Groesbeck, said its brands are performing well and posted a 28.5% increase in sales at superstores in Q2 2020 compared to 14% in Q2 2019. The company expects to post higher sales of brands going forward because it has expanded the cultivation to supply its popular Medizin line.

Planet 13 is also enjoying success in the wholesale space after it commenced the supply in June 2020. The customers can buy its products across 33 Nevada based dispensaries. Its top-performing SKUs include concentrates, edibles, and beverages.

Begins upward journey

Planet 13 posted monthly revenues of $7 million in July and August 2020. The company will soon inaugurate Medizin dispensary and Santa Ana next year.

Planet 13 implemented operational enhancement in Las Vegas. It is helping the company for higher conversion of visitors into potential customers. The company also made improvements at the Superstore to attract residents in Las Vegas.

Planet 13 generated revenues of $1.7 million in July 2020 from curbside pickup and delivery. It represents 17% of the overall sales.

Planet 13 also strengthened its cash balance to $22.7 million. Its total assets also increased to $81.9 million. The company acquired Santa Ana on May 21, 2020. It also mobilized CAD 11.5 million through bought deal offering on July 13, 2020.

Planet 13 took over 45,000 Sq.Ft. indoor cultivation on July 17, 2020. It also received a dispensary license in Nevada on August 10, 2020.

The vertically integrated cannabis company based in Nevada – Planet 13 engages in manufacturing, cultivation, and dispensary operations, mainly in Las Vegas.

Continue Reading


Medical Marijuana Inc (OTCMKTS:MJNA) Sells Over 1.6 Billion Hemp Derived Cannabidiol As Consumers Prefer CBD Oil



Medical Marijuana Inc (OTCMKTS:MJNA) achieved a significant milestone of selling over $1.6 billion mg of CBD. It is on the backdrop of an increased percentage of consumers preferring CBD oil during the ongoing coronavirus. Around 15% of consumers intend to use a higher dosage of cannabidiol.

Real Scientific Hemp Oil

Dr. Stuart Titus, CEO of Medical Marijuana, said the company supplied Real Scientific Hemp Oil, an oral version of high potency cannabidiol, for 10 years. According to the global media coverage, several customers across the world demonstrated positive experiences in using its products for almost 5 years.

Satisfies high consumer demand for CBD oil

Stuart further said several other products that are sold as hemp-based products do not contain cannabidiol. They are just a CBD isolate. Medical Marijuana is committed to delivering high-quality cannabidiol oil and satisfying consumer demand.

CBD products are popular among Americans. Around 33% of people in the US have used cannabidiol products at least once in their life. Blake Schroeder, COO of Medical Marijuana, said CBD derived products and cannabidiol products are now part of everyone’s life in the US to maintain wellness.

Stuart features in Reuters

Stuart featured in Reuters, a global financial news hub, on August 11, 2020, and discussed the present landscape of M&A (mergers and acquisitions) in the cannabis space.

An article in Reuters provided an insight into how the cannabis companies fare after the coronavirus, which boosted demand for cannabis. According to Stuart, the cannabis industries celebrate financial success at these difficult times. The same trend expects to continue for some more months before M&A takes place in the industry.

On the expectation of legalization of cannabis in the US after November 2020, the presidential election, the cannabis retailers are busy finalizing the deals. A cautious approach is expected in spending the funds in the aftermath.

Stuart further stated the company engages in developing sales strategies to maintain profitability and exploring new opportunities for enhancing its product line.

Promotions of top-level executives

Medical Marijuana promoted Todd Morrow as CFIO (Chief Financial and Information Officer). It also improved morale by promoting Michelle Sides, Esq. as CLO.

Continue Reading

Trending Stories